NPT100-18A rescues mitochondrial oxidative stress and neuronal degeneration in human iPSC-based Parkinson’s model by Julian E. Alecu, Veronika Sigutova, Razvan-Marius Brazdis, Sandra Lörentz, Marios Evangelos Bogiongko, Anara Nursaitova, Martin Regensburger, Laurent Roybon, Kerstin M. Galler, Wolfgang Wrasidlo, Beate Winner, Iryna Prots

Get full text

Circulating Soluble ST2 Predicts All-Cause Mortality in Severe Heart Failure Patients with an Implantable Cardioverter Defibrillator by Zhi-wei Hou, Hai-bo Yu, Yan-chun Liang, Yang Gao, Guo-qing Xu, Min Wu, Zhu Mei, Zu-lu Wang, Zhi-guo Li, Yu-ying Li, Hai-xu Song, Jia-yin Li, Ya-ling Han

“…Although implantable cardioverter defibrillator (ICD) therapies have reduced mortality among the high-risk HF population, it is necessary to determine whether certain factors can predict mortality even after cardiac device implantation. …”
Get full text

Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 express... by Fei Yang, Min Dan, Jindan Shi, Ling Fan, Haoluo Zhang, Tiantian Jian, Kelu Lei, Yue Wang, Juan Xin, Zhigang Yu, Wei Chen

“…BackgroundPD-1 inhibitors have shown promising efficacy in enhancing OS and AEs as second-line therapies for patients with advanced esophageal squamous cell carcinoma (ESCC). …”
Get full text

Clozapine for Treatment-Resistant Disruptive Behaviors in Youths With Autism Spectrum Disorder Aged 10-17 Years: Protocol for an Open-Label Trial by André Luiz Schuh Teixeira da Rosa, Marina Ribeiro Barreto da Costa, Gabriela Bezerra Sorato, Felipe de Moura Manjabosco, Érica Bonganhi de Bem, Lucas Dellazari, Arthur Bezerra Falcão, Lucas de Oliveira Cia, Olivia Sorato Bezerra, Rogério Boff Borges, Luis Augusto Rohde, Ana Soledade Graeff-Martins

“…ConclusionsThe urgent need for effective pharmacological therapies in mitigating treatment-resistant DB in pediatric patients with ASD underscores the importance of this research. …”
Get full text

Effet de l'illumination proche infra-rouge intracérébrale chez des primates MPTP by Fannie Darlot, Cécile Moro, Napoléon Torres‑Martinez, Claude Chabrol, Florian Reinhart, Diane Agay, Thomas Costecalde, John Mitrofanis, Alim‑Louis Benabid

“…Des résultats récents ont rapporté des propriétés neuroprotectrices de la thérapie par illumination de faible intensité (ou photobiomodulation par lumière proche infrarouge (NIR)) par l'activation de la cytochrome C oxydase et la synthèse d'ATP dans les cellules endommagées. …”
Get full text

The impact of trauma and how to intervene: a narrative review of psychotraumatology over the past 15 years by Miranda Olff, Irma Hein, Ananda B. Amstadter, Cherie Armour, Marianne Skogbrott Birkeland, Eric Bui, Marylene Cloitre, Anke Ehlers, Julian D. Ford, Talya Greene, Maj Hansen, Nathaniel G. Harnett, Debra Kaminer, Catrin Lewis, Alessandra Minelli, Barbara Niles, Nicole R. Nugent, Neil Roberts, Matthew Price, Anthony N. Reffi, Soraya Seedat, Antonia V. Seligowski, Anka A. Vujanovic

Get full text

The AMD-associated genetic polymorphism CFH Y402H confers vulnerability to Hydroquinone-induced stress in iPSC-RPE cells by Angela Armento, Inga Sonntag, Ana-Cristina Almansa-Garcia, Merve Sen, Sylvia Bolz, Blanca Arango-Gonzalez, Ellen Kilger, Ruchi Sharma, Kapil Bharti, Rosario Fernandez-Godino, Berta de la Cerda, Simon J. Clark, Simon J. Clark, Simon J. Clark, Marius Ueffing

Get full text

Thrombus composition and its implication in ischemic stroke assessment and revascularization treatments by Juan Marta-Enguita, Florencio J.D. Machado, Josune Orbe, Roberto Muñoz

“…Understanding of these pathways has enabled the development of adjuvant therapies capable of enhancing current fibrinolytic drugs and/or increasing the efficacy of endovascular treatments. …”
Get full text

Estimation of the incidence of invasive meningococcal disease using a capture–recapture model based on two independent surveillance systems in Catalonia, Spain by Pilar Ciruela, Carmen Munoz-Almagro, Cristina Rius, Tomas Pumarola, Frederic Gomez-Bertomeu, Núria Soldevila, Ángela Domínguez, LAURA RUIZ, Ana Calderon, Ana Martinez, M Ángeles Domínguez, Mercé Garcia, Dionisia Fontanals, Gloria Carmona, Pere Godoy, Goretti Sauca, Jordi Vila, Marta Vilaró, Mireia Jané, Tomás Garcia, Sergi Hernández, Maria Teresa Bastida, Frederic Ballester, Isabel Pujol, Miguel Angel Benítez, Alba Cebollero, Jordi Bosch, Margarida Curriu, Fe Tubau Quintano, Jose Manuel Ramirez, Ma Jose Fusté, Carme Gallés, Pilar Hernandez Pérez, ElisendaCapdevila GildeBernabe, Paula Gassiot, Araceli González-Cuevas, Marius Juanpere, Amaresch Perez Arguello, Carmina Martí, Nuria Margall, Lurdes Matas, Montserrat Giménez, Montserrat Morta, Gloria Trujillo, Silvia Noguer, Montserrat Olsina, Amaia Oteiza Ubanell, Pepa Perez, Mar Olga Pérez-Moreno, Juanjo Gonzales, Xavier Raga, Mercè Ribelles, Esther Sanfeliu, Isabel Sanfeliu, Anna Vilamala, César Arias, Irene Barrabeig, Neus Camps, Mònica Carol, Núria Follia, Sofia Minguell, Ignasi Parron, Ma Rosa Sala-Farré, Ariadna Rovira

Get full text

LRH‐1/NR5A2 targets mitochondrial dynamics to reprogram type 1 diabetes macrophages and dendritic cells into an immune tolerance phenotype by Nadia Cobo‐Vuilleumier, Silvia Rodríguez‐Fernandez, Livia López‐Noriega, Petra I. Lorenzo, Jaime M. Franco, Christian C. Lachaud, Eugenia Martin Vazquez, Raquel Araujo Legido, Akaitz Dorronsoro, Raul López‐Férnandez‐Sobrino, Beatriz Fernández‐Santos, Carmen Espejo Serrano, Daniel Salas‐Lloret, Nila vanOverbeek, Mireia Ramos‐Rodriguez, Carmen Mateo‐Rodríguez, Lucia Hidalgo, Sandra Marin‐Canas, Rita Nano, Ana I. Arroba, Antonio Campos Caro, Alfred CO Vertegaal, Alejandro Martín‐Montalvo, Franz Martín, Manuel Aguilar‐Diosdado, Lorenzo Piemonti, Lorenzo Pasquali, Roman González Prieto, Maria Isabel García Sánchez, Decio L. Eizirik, Maria Asuncion Martínez‐Brocca, Marta Vives‐Pi, Benoit R. Gauthier

“…Abstract Background The complex aetiology of type 1 diabetes (T1D), characterised by a detrimental cross‐talk between the immune system and insulin‐producing beta cells, has hindered the development of effective disease‐modifying therapies. The discovery that the pharmacological activation of LRH‐1/NR5A2 can reverse hyperglycaemia in mouse models of T1D by attenuating the autoimmune attack coupled to beta cell survival/regeneration prompted us to investigate whether immune tolerisation could be translated to individuals with T1D by LRH‐1/NR5A2 activation and improve islet survival. …”
Get full text

Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure by Masatake Kobayashi, Susan Stienen, Jozine M. terMaaten, Kenneth Dickstein, Nilesh J. Samani, Chim C. Lang, Leong L. Ng, Stefan D. Anker, Macro Metra, Gregoire Preud'homme, Kevin Duarte, Zohra Lamiral, Nicolas Girerd, Patrick Rossignol, Dirk J. vanVeldhuisen, Adriaan A. Voors, Faiez Zannad, João Pedro Ferreira

Get full text

Systematic Sex-Based Inequity in the MELD Score-Based Allocation System for Liver Transplantation in Germany by Leke Wiering, Leke Wiering, Annette Aigner, Marieke van Rosmalen, Brigitta Globke, Brigitta Globke, Tomasz Dziodzio, Nathanael Raschzok, Nathanael Raschzok, Münevver Demir, Wenzel Schöning, Frank Tacke, Petra Reinke, Johann Pratschke, Robert Öllinger, Paul V. Ritschl, Paul V. Ritschl

Get full text

Survey on first-line therapeutic management of relapsing–remitting multiple sclerosis in clinical practice in Spain by M. Llaneza, G. Fontes, L. Benedito-Palos, E. Moral

“…Introduction: Current therapies for relapsing–remitting multiple sclerosis (RRMS) help reduce morbidity and delay disease progression. …”
Get full text

Revealing the biological features of the axolotl pancreas as a new research model by Hui Ma, Hui Ma, Hui Ma, Guangcong Peng, Yan Hu, Binbin Lu, Binbin Lu, Yiying Zheng, Yingxian Wu, Weimin Feng, Yu Shi, Xiangyu Pan, Li Song, Ina Stützer, Yanmei Liu, Jifeng Fei, Jifeng Fei, Jifeng Fei

Get full text

Case Reports: The core of practice-based evidence by Antonio Villa

“…Furthermore, a case report is often the most important source of information on adverse effects following therapies. According to Greenwalt, case reports can explain a complex reality, because “a carefully documented study of an unusual patient represents an experiment of nature that may be the opportunity to explain a long-recorded but unexplained clinical mystery” [3]. …”
Get full text

T Cell-Derived Apoptotic Extracellular Vesicles Ameliorate Bone Loss via CD39 and CD73-Mediated ATP Hydrolysis by Yang X, Zhou Y, Zhou F, Bao L, Wang Z, Li Z, Ding F, Kuang H, Liu H, Tan S, Qiu X, Jing H, Liu S, Ma D

“…Our data underscore the substantive role of T cell-derived ApoEVs to treat osteoporosis, thus providing new ideas for the development of ApoEVs-based therapies in tissue regeneration. Keywords: T cell apoptosis, apoptotic extracellular vesicles, CD39, CD73, adenosine, bone regeneration…”
Get full text

Optimizing Prescribing for Individuals With Type 2 Diabetes and Chronic Kidney Disease Through the Development and Validation of Algorithms for Community Pharmacists by Jennifer Morris, Marisa Battistella, Karthik Tennankore, Steven Soroka, Cynthia Kendell, Penelope Poyah, Keigan More, Mathew Grandy, Thomas Ransom, Natalie Kennie-Kaulbach, Daniel Rainkie, Jaclyn Tran, Syed Sibte Raza Abidi, Samina Abidi, Nicole Fulford, Heather Neville, Heather Naylor, Lisa Woodill, Andrea Bishop, Glenn Rodrigues, Diane Harpell, Michelle Stewart, Jo-Anne Wilson

“…Objective: The objective was to develop and validate pharmacist algorithms to confirm T2D and CKD and to prescribe guideline-directed therapies for individuals with an estimated glomerular filtration rate (eGFR) of 30 to 60 mL/min/1.73 m² in community pharmacy primary care clinics in Nova Scotia. …”
Get full text

Contextual Vulnerability Should Guide Fair Subject Selection in Xenotransplantation Clinical Trials by Gianna Strand

“…This potential subject population includes individuals with broadly reactive antibodies who are unlikely to match to a donor organ and individuals with anatomical contraindications who face prohibitive risks with standard allografts or bridging therapies.[xl] This subject population aligns with the FDA recommendation to enroll subjects for whom safe and effective alternatives are not available.…”
Get full text